

























Given the frequency at which DNA lesions occur 
(approximately 10
4 per cell per day [1]), a complex 
system of damage detection and repair is required in 
order to preserve the integrity of the genome.  This 
system is termed the DNA damage response (DDR), 
and encompasses: the recognition of DNA damage; the 
transduction of signals through appropriate pathways; 
and the activation of cellular responses ranging from 
DNA repair and chromatin remodeling to the activation 
of cell death if the damage is irreparable [2-4].   
 
DNA lesions can be caused by either endogenous 
(reactive oxygen species (ROS) resulting from 
metabolic processes) or exogenous (ionizing radiation 
(IR), UV) agents.  The repair pathway activated in res-
ponse to such agents is dependent on the type of lesion 
generated.  Base excision repair (BER) and nucleotide 
excision repair (NER) pathways are typically activated 
in response to damage to individual DNA bases [5], 
while breaks in one (SSBs) or both (DSBs) require 
repair by mechanisms such as homologous recombin-
ation (HR), single strand annealing (SSA) or non-homo-
logous end joining (NHEJ).  As these processes are 
reviewed elsewhere [6-8], they will not be covered by 
this review.  Instead, it will focus on the interplay bet-
ween some of the key components of the signaling 
pathways preceding DNA repair, the roles of these 
proteins in  the  maintenance  of  genomic  stability, and 
 
 























will finally  seek to address the  role of  the DDR in 
both cancer and ageing. 
 
The DDR: functions of and interplay between the 
key players 
 
The DDR comprises multiple proteins, and a 
complicated network of signaling pathways to ensure 
that the processes of DNA repair, cell cycle arrest or  
the triggering of the apoptotic cascade are correctly 
regulated.  Since the individual elements of the DDR 
have been reviewed at length elsewhere, this paper will 
aim to give a brief overview of the key components in 
order to further discuss how the DDR can be targeted to 
treat cancer. 
 
ATM.  ATM (ataxia telangiectasia mutated) is a mem-
ber of the phosphatidylinositol 3-kinase related family 
of serine/threonine protein kinases (PIKKs) [9].  ATM 
is critical in the immediate response of cells to DSBs 
and the subsequent switch to ATR activation following 
DNA end resection [10].  Mutation of ATM in humans 
leads to the condition ataxia telangiectasia (A-T), which 
is characterized by: progressive neurodegeneration; 
immunodeficiency; genomic instability; clinical radio-
sensitivity; and a predisposition to cancer, in particular 
lymphomas as a result of inappropriate signaling foll-
owing programmed DSBs during V(D)J recombination 
in T-cells [11, 12].  The recruitment of ATM following 
DSBs is mediated by the Mre11/Rad50/NBS1 (MRN) 
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and relaxation of the double helix torsional stress [14].  
Acetylation of ATM by the histone acetylase Tip60 
stimulates ATM autophosphorylation, resulting in the 
dissociation of inactive homodimers into monomers, 
and the phosphorylation of downstream substrates  [15]. 
 
Multiple proteins have been shown to be 
phosphorylated downstream of ATM, including the 
known tumor suppressor protein p53, structural main-
tenance of chromosomes (SMC) 1, which is known to 
engage the S phase checkpoint, the breast and ovarian 
cancer susceptibility protein BRCA1 and the checkpoint 
kinase Chk2 [16-19].  These will be discussed in more 
detail later. 
 
ATR.  ATR (ATM-Rad3-related) is also a member of 
the PIKK family, and while being related to ATM, 
plays a distinct role in the DDR.  Loss of ATR has been 
shown in mouse models to convey embryonic lethality 
[20], suggesting a critical role for the protein in 
development.  Humans surviving with ATR mutations 
display a condition called Seckel syndrome, the phenol-
type of which includes growth retardation and micro-
cephaly [21]. 
 
The initial step in ATR signaling is the binding of 
replication protein A (RPA) to single stranded DNA 
(ssDNA), which recruits the ATR-ATRIP complex to 
the DNA damage.  The recognition of neighboring 
DNA ends by the RAD9-RAD1-HUS1 (9-1-1) complex 
brings the protein TOPBP1 into the vicinity of ATR-
ATRIP to stimulate ATR activation [22-24].  As with 
ATM, this activation results in the phosphorylation of 
multiple substrates, such as Chk1 [25].  There is some 
overlap between the ATM and ATR pathways at the 
substrate level, with both having been shown to phos-
phorylate various substrates, including p53 and BRCA1 
[26-28]. 
 
BRCA1.  Following DNA strand breaks, BRCA1 has 
been found to localize to IR-induced nuclear foci.  This 
localization has been shown to regulate the activation 
state of many proteins downstream of both  ATM and 
ATR, thereby suggesting a possible means of cross-talk 
and overlap between the two pathways [29].  BRCA1 
has also been found to form distinct macromolec-         
ular complexes, which allow BRCA1 to participate in 
multiple DDR-related functions, including regulation of 
the G1/S and G2/M checkpoints, and the repair of DSBs 
by HR (reviewed in [30]). 
 
The induction of G1/S arrest by BRCA1 is known to 
require several other proteins.  The inhibition of gene 
transcription is regulated by the interaction of 
hyposphosphorylated pRB with the E2F transcription 
factor.  This hyposphosphorylated state of pRB is 
thought to be maintained by its interaction with BRCA1 
[31].  Cell cycle arrest may also be a result of the regul-
ation of p53 phosphorylation by the BRCA1-BARD1 
complex, as the phosphorylation of p53 is critical for its 
activation [32]. 
 
The intra-S phase checkpoint is also regulated by 
BRCA1, through the BRCA1B complex containing 
BRCA1, BACH1 and TOPBP1 (reviewed in [30]).  This 
complex mediates the firing of replication origins by 
regulating the loading of the licensing factor CDC45L 
onto the DNA [33].  The BACH1-TOPBP1 interaction 
has also been shown to be essential for the optimal 
loading of RPA onto chromatin, suggesting that BRCA1 
is critical in the maintenance of DNA replication 
through regulating the response of cells to stalled 
replication forks [34]. 
 
The BRCA1C complex, comprising BRCA1, the 
carboxy-terminal binding protein interacting protein 
(CtIP) and the MRN complex, has an essential 
function in regulating the G2/M checkpoint.  The 
interaction of CtIP and MRN has been found to 
regulate the resection of DNA ends [35], a process also 
mediated by BRCA1 [36, 37], thereby regulating the 
function of the ATR-ATRIP complex at regions of 
ssDNA, and so regulating the progression of the cell 
through the G2/M checkpoint. 
 
BRIT1.  Another protein recently shown to interact with 
multiple members of the DDR is the repressor of 
hTERT, BRIT1.  This protein functions at multiple stag-
es in the DDR, including the regulation of the G2/M 
checkpoint, stimulation of BRCA1 and Chk1 expression 
and the interaction and recruitment of the BRCA2/ 
RAD51 complex for the execution of HR.  The docu-
mented failure of various DDR proteins including 
NBS1, phosphorylated ATM and ATR to localize to 
sites of DNA damage in the absence of BRIT1 suggests 
that BRIT1 functions upstream of these proteins as a 
scaffold to bridge phosphorylated H2AX and the DDR 
(reviewed in [38]). 
 
In 2009, BRIT1 was shown to recruit the SWI-SNF 
chromatin remodeling complex to sites of DNA 
damage in an ATM/ATR-dependent manner.  This rec-
ruitment is thought to facilitate the unwinding of 
chromatin following DNA damage, thereby allowing 
access of the required repair proteins.  This shows that 
BRIT1, therefore, plays a critical role in both HR and 
NHEJ mediated repair [39]. 
 
The  interplay  between  BRIT1, BRCA1 and the other 
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rated in figure 1. 
 
Checkpoint kinases.  The checkpoint kinases Chk1 and 
Chk2 are widely considered to be the major effectors of 
the DDR in regulating cell cycle checkpoints and 
coordinating this with DNA repair. 
 
As with ATR, Chk1 has found to be critical for 
embryonic development, suggesting that it is active at 
multiple stages within the cell cycle [40].  In response 
to DNA damage and ATR activation, the adaptor 
molecule claspin is phosphorylated, which results in the 
recruitment of Chk1 to ATR.  Following its phosphoryl-
ation, Chk1 is released from the chromatin in its active 
form, allowing it to phosphorylate the CDC25 family of 
phosphatases [41].  This targets the phosphatase for 
degradation via the ubiquitin/proteasome pathway, and 
so prevents it from dephosphorylating and activating 
CDKs, leading to cell cycle arrest at either the G1/S, 
intra-S phase or G2/M checkpoint [42] (Fig. 2). 
 
In contrast, Chk2 is not considered to be vital for 
































following DNA damage.  Although Chk2 has been 
found to phosphorylate CDC25A, its role in the DDR is 
thought to be related more to its effect on p53 
stabilization than cell cycle arrest [43]. 
 
p53.   The frequency of p53 mutation and loss in human 
cancers suggests a critical role for p53 in the mainten-
ance of genomic integrity.  p53 can be phosphorylated 
by a number of DDR proteins, including ATM, ATR 
and Chk2 [17, 44, 45].  This phosphorylation reduces 
the binding of p53 to MDM2, resulting in stabilization 
and activation of the p53 protein. 
 
One of the key activities of p53 is thought to be the 
induction of expression of p21, a known regulator of 
both the G1/S and G2/M transitions through its 
inhibition of cyclin-dependent kinases (CDK) [46].  A 
further role for p53 in tumor suppression is the 
regulation of the apoptotic cell death pathway.   
However, this falls outside the scope of this review and 
so will not be discussed here.  Figure 2 shows an 
overview of the pathways connecting the checkpoint 

















































Figure  2.  The  downstream  effectors  of  the  DDR.  After 
activation by ATR, Chk1 phosphorylates the CDC25 family 
of  phosphatases,  thereby  targeting  them  for  ubiquityn‐
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Over 30 years ago it was established that cells within a 
tumor are derived from a single genetically unstable 
cell, and that the population as a whole continues to 
acquire further chromosomal abnormalities over time 
[47].  However, the precise mechanisms of acquisition 
of these abnormalities have remained unclear.   
Hereditary cancers are often characterized by the 
presence of a specific type of genomic instability, 
termed chromosomal instability (CIN).  In these 
cancers, CIN can often be attributed to mutation in 
DNA repair genes, suggesting that the drive behind 
tumor development is the increase in spontaneous 
genetic mutation resulting from a lack of appropriate 
management of DNA damage [48].  A second form of 
genomic instability, termed microsatellite instability 
(MIN), is also associated with defects in DNA repair, 
namely the mismatch repair system [49].  However, in 
non-hereditary sporadic tumors, the picture is less clear. 
 
Many of the DDR components including BRCA1 [50] 
and BRIT1 [38] are known to be lost or mutated in 
human tumors, and patients suffering from ataxia 
telangiectasia are known to be susceptible to tumors, as 
mentioned above. 
 
While the loss of BRCA1 has been shown to lead to the 
development of mammary tumors in mouse models, the 
genetic diversity within those tumors suggests that the 
loss of BRCA1 is not directly responsible for 
tumorigenesis.  It is more likely, therefore, that the role 
of BRCA1 in the initiation of cancer is a result of its 
effects on DNA repair and the maintenance of genomic 
integrity [51].  These mouse models, coupled with the 
study of human BRCA1 -/- tumors, has revealed a 
prevalence for p53 mutations in these tumors, which is 
likely to be caused by the decrease in genomic stability 
associated with the defects in DNA repair (reviewed in 
[52]). 
 
Similar to BRCA1 -/- tumors, BRIT1 -/- tumors also 
display numerous chromosomal aberrations.  Interest-
ingly, BRIT1 is expressed on the short arm of 
chromosome 8, a region which has been found to be 
altered in various forms of cancer [53-56].  A sig-
nificant increase in cancer susceptibility was also noted 
in mice crossed from both BRIT1 -/- and p53 -/- 
backgrounds [38].  Taken together, these data suggest 
that the loss of cell cycle checkpoints confers a 
selection advantage to cells with DNA repair defects, 
thereby triggering tumorigenesis in genetically unstable 
cells.  The reduction in BRIT1 expression correlates 
significantly with an increase in genomic instability,       
as well as with the metastatic potential of the tumor. 
Further studies will be required to determine whether 
this involvement in metastasis is a result of acquired 
genetic mutations resulting from DNA repair defects, or 
whether other binding partners of BRIT1 are required 
for this process. 
 
The DDR and ageing 
 
In addition to its role in the maintenance of genomic 
integrity, the DDR has been hypothesized to play a 
critical role in organismal ageing.  Ageing, resulting 
from the accumulation of damage to molecules, cells, 
organs and tissues over time, is believed to be caused by 
two cellular processes: senescence and apoptosis. 
 
Senescence.  Senescence was first described by 
Hayflick and Moorhead in 1961 when it was noted that 
fibroblasts entered a state of permanent growth arrest 
following serial cultivation; a fate that was not shared 
by cancer cells [57].  Further study has revealed differ-
ent forms of senescence, namely replicative senescence 
and oncogene-induced senescence, both of which 
involve aspects of the DDR. 
 
Replicative senescence results from the progressive 
shortening of telomeres with repeated rounds of cell 
replication.  In 2007, Feldser and Greider demonstrated 
that the shortening of telomeres in mice was related to a 
suppression of tumor incidence as a result of induction 
of a p53-dependent senescence pathway.  This p53 
response to critically shortened telomeres has been 
demonstrated to be a result of activation of the DNA 
damage response (reviewed in [58]), since the short-
ening of telomeres results in their uncapping and their 
recognition as damaged DNA [59]. 
 
However, the role of p53 in the induction of a senescent 
phenotype has been debated by recent studies, which 
have shown that p53 can either activate or suppress 
senescence.  The determination of cell fate has been 
postulated to depend on the specific transcriptional 
activities of p53.  Several recent reports have proposed 
a mechanism by which p21-induced cell cycle arrest 
could be converted into either a quiescent or senescent 
phenotype, depending on the activity of p53 and its 
inhibition of the protein kinase mammalian target of 
rapamycin (mTOR) [60-62].  Briefly, it has been 
suggested that under conditions where p53 is able to 
inhibit the mTOR pathway, cells will become quiescent.  
However, when p53 is unable to inhibit mTOR 
signaling, the drive will be towards senescence.  A 
further level of complexity to the role of p53 in cell fate 
determination was also suggested by Vigneron et al. 
[63].  This publication highlighted the importance of the 
histone deacetylase  Sirt1 in the regulation of p53 
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senescence by chronic DDR signaling may be linked to 
decreased levels of Sirt, and so increased levels of p53 
acetylation.  The results of these studies are summarized 
in figure 3. 
 
p53 is not the only DNA damage response protein to be 
associated with replicative senescence.  Studies in mice 
have shown that the deletion of ATM causes an increase 
in both chromosomal end-to-end fusion events and cell 
cycle-dependent telomere loss.  These events were ac-
companied by a premature ageing phenotype, with 
symptoms including increased hair graying, alopecia 
and marked weight loss [64].  A further study also dem-
onstrated that mice expressing a mutant form of BRCA1 
also show premature ageing, accompanied by an 
increase in cellular senescence [65].  The ageing phen-
otype in this model was also accompanied by an 
increased susceptibility to certain cancers.  While this 
might seem contradictory to the enhanced senescence in 
these mice, senescent cells have been noted to modify 
the tissue microenvironment by the secretion of 
degradative enzymes, cytokines and growth factors.   
This is thought to synergize with the accumulation of 
DNA damage over time to encourage cancer growth 
[66]. 
 
Senescence can also be induced by the overexpression 
of oncogenes.  This has recently been reviewed 
elsewhere [67] and so will not be discussed in de-     

























induce  senescence  by  multiple means,  including  the 
induction of DNA damage resulting from both the 
generation of reactive oxygen species (ROS) and the 
hyper-replication of DNA.  Both of these mechanisms 
activate the DDR, which induces senescence as 
described for replicative senescence above. 
 
Apoptosis.  The accumulation of DNA damage does not 
necessarily lead to cellular senescence.  The activation 
of p53 by DNA damage has been well documented, and 
its role in the regulation of expression of pro-apoptotic 
proteins has been recently reviewed [68].  The fact that 
the majority of tumors lose the expression of functional 
p53 underlines its importance as a regulator of cell 
death processes.  In the context of ageing, the apoptotic 
function associated with p53 activation has been 
previously documented in terms of the decline of the 
immune system associated with an increase in apoptosis 
[69-71].  A mouse model in which p53 is constitutively 
activated also showed that, while high levels of p53 
protect against cancer, it also accelerates the ageing 
process by reducing the mass of various tissues [72].  
The human condition ataxia-telangiectasia, which 
results from mutations in ATM, is associated with 
substantial neurodegeneration.  This has been shown in 
a mouse model to result from an accumulation of 
neurons harboring genomic damage, due to the inability 
of the mutant ATM protein to stimulate the p53 
apoptotic cascade [73].  Chk2 has also been shown           
to regulate apoptosis in a p53-dependent manner in  
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The DDR is a complex network of proteins, comprising 
DNA damage recognition, signal transduction, 
transcriptional regulation, cell cycle control and DNA 
repair.  The maintenance of the DDR is essential for 
faithful replication of the genome, and so is critical for 
cellular survival.  The loss of certain DDR components 
can lead to an increased susceptibility to cancer due to 
the ensuing genomic instability and the subsequent 
mutation to genes required for cellular replication and 
division.  The DDR is also involved in the induction of 
senescence and apoptosis when the damage cannot be 
repaired.  While this can prolong longevity during early 
stages of life due to the suppression of tumorigenesis, it 
may become detrimental in ageing due to the loss of 
stem and progenitor cells for renewal.  This is a 
phenomenon referred to as antagonistic pleiotropy, and 
it highlights the importance of carefully balanced cell 
signaling cascades and regulatory systems in the 
maintenance of survival.  Further studies of the roles of 
DDR-associated proteins, along with the discovery of 
new ones, will therefore not only enhance our 
understanding of cancer and mechanisms to treat it, but 
will also enhance our understanding of the ageing 
process.  This may uncover ways to treat premature 
ageing or other age-related pathologies, such as the 
decline of the immune system in the elderly. 
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